### Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai – 400 063, Maharashtra, INDIA.

Tel.: (91-22) 4324 4324 Fax: (91-22) 4324 4343

Website: www.sunpharma.com CIN: L24230GJ1993PLC019050



# December 01, 2020

National Stock Exchange of India Ltd.,

Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra Kurla Complex,

Bandra (East), Mumbai – 400 051.

**BSE** Limited,

Market Operations Dept. P. J. Towers,

Dalal Street, Mumbai - 400 001.

**Scrip Code: 524715** 

**Scrip Symbol: SUNPHARMA** 

Dear Sirs,

Sub: Disclosure under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the details of related party transactions on consolidated basis for the half year ended September 30, 2020 in the format specified in the relevant accounting standards for annual results.

This is for your information and record.

Thanking you,

Yours faithfully,

For Sun Pharmaceutical Industries Limited

Ashok I. Bhuta **Compliance Officer** 

Encl: As above

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

### SUN PHARMACEUTICAL INDUSTRIES LIMITED

Related Party disclosure on a consolidated basis - Half year ended September 30, 2020

### Names of related parties where there are transactions and description of relationships

### a Key Management Personnel (KMP)

Dilip Shantilal Shanghvi

Israel Makov

Kalyanasundaram Iyer Natesan Subramanian

Sailesh Trambaklal Desai

Sudhir Vrundavandas Valia

Managing Director (DIN: 00005588)

Chairman and Non- Executive Director (Non- Independent)

(DIN: 05299764) Wholetime Director (DIN: 00179072) Wholetime Director (DIN: 00005443)

Non-Executive Director and Non-Independent Director

(DIN: 00005561)

### **b** Relatives of Key Management Personnel

Aalok Shanghvi Vidhi Shanghvi

### c Others (Entities in which the KMP and Relatives of KMP have control or significant influence)

Alfa Infraprop Private Limited

Fortune Integrated Assets Finance Ltd

Kism Textiles Private Limited

Makov Associates Limited

PV Power Technologies Private Limited

Shanghvi Finance Private Limited

Sidmak Laboratories (India) Private Limited

Sun Petrochemicals Private Limited

Sun Pharma Advanced Research Company Limited

United Medisales Private Limited

#### d Joint Venture

Artes Biotechnology GmbH

#### e Associates

Dy Py Institute LLC

Tarsius Pharma Ltd

### f Unconsolidated Subsidiary

Foundation for Disease Elimination and Control of India

## SUN PHARMACEUTICAL INDUSTRIES LIMITED

Transactions during half year ended September 30, 2020 with related parties :	₹ In Millio
	Half Year ended
	September 30, 2020
Purchase of goods	174.
Others	174.
Purchase of property, plant and equipment and other intangible assets	1,525.
Others	1,525.
Revenue from contracts with customers, net of returns	90.
Others	90.
Sale of property, plant and equipment and other intangible assets	1.
Others	1.
Receiving of service	696
Joint venture	1
Others	694
Reimbursement of expenses - Paid	8
Associate	5
Joint venture	1
Others	1
Rendering of service	137
Others	137
Reimbursement of expenses - Received	133
Others	133
Investment in Associate	185
Associate	185.
Lease Rental and hire charges ( Income )	11
Others	11
Rent expense / Payment towards Lease Liabilities	4
Others	4
Remuneration/ compensation	158
Key management personnel	141
Relatives of Key management personnel	16
Donation	22
Unconsolidated subsidiary	22

### NOTE:

- 1 Drawn in accordance with applicable accounting standards for the period Half year ended September 2020.
- 2 Key management Personnel (KMP) and Relatives of KMP who are under the employment of the Company are entitled to post employment benefits and other long term employee benefits recognised as per Ind AS 19 'Employee Benefits'. As these employee benefits are lump sum amount provided on the basis of actuarial valuation, the same is not included above and there is no Share-based payments to key management personnel and relatives of KMP.